the Floor or in the Lab

During internal assessments, certain symptoms may indicate supplier WHO GMP non-compliance. Identifying these signals early can help mitigate risks. Common indicators include:

• Deviation Reports: Increase in out-of-spec (OOS) results and non-conformance reports related to supplier materials.
• Quality Metrics: Trends showing elevated rejection rates or increase in complaints regarding quality issues.
• Audit Findings: Notable issues identified during supplier audits, highlighting lapses in quality systems (QMS).
• Regulatory Citations: Recent non-compliance notifications from WHO or other regulatory bodies regarding the supplier.

Likely Causes

Understanding the potential causes of supplier WHO GMP non-compliance can aid in effective decision-making during internal assessments. The causes can be categorized into six primary areas:

Materials

• Substandard raw materials or active pharmaceutical ingredients (APIs).
• Lack of documentation supporting material specifications.

Method

• Non-standard manufacturing methods employed by the supplier.
• Poorly defined processes leading to variability.

Machine

• Outdated or improperly calibrated equipment.
• Lack of maintenance leading to equipment failures.

Man

• Inadequate training of personnel regarding GMP requirements.
• High turnover rates resulting in knowledge gaps.

Measurement

• Poor quality control measures in place for process monitoring.
• Inconsistent measurement techniques used during production.

Environment

• Non-compliant facility conditions (cleaning, storage, humidity control).
• Failure to maintain adequate hygiene standards in production areas.

Immediate Containment Actions (first 60 minutes)

Upon identifying potential non-compliance, swift action is necessary to contain the issue. Key steps to follow:

• Cease production using materials or components from the non-compliant supplier.
• Initiate a hold on all affected products to prevent distribution.
• Gather a cross-functional team, including QC, QA, and Production, to investigate the issue.
• Implement immediate temporary measures, such as increased inspection of incoming materials from the supplier.

Investigation Workflow

The investigation should follow a systematic workflow to identify the root of the compliance issue. Key actions include:

• Data Collection: Review batch records, deviation reports, and audit findings related to the supplier.
• Engage with the supplier directly for clarification and additional documentation.
• Develop a timeline of events to trace when the non-compliance may have originated.
• Interview relevant personnel to gather insights on any anomalies observed during production.

Root Cause Tools

Utilizing structured root cause analysis tools helps in effectively identifying the underlying issues. The following tools should be considered:

Tool	Description	When to Use
5-Why	A sequential questioning technique to explore cause-and-effect relationships.	Best for surface-level issues that require deep inspection.
Fishbone Diagram	A visual representation that categorizes potential causes for a specific problem.	Useful for brainstorming sessions involving a team to identify various factors.
Fault Tree Analysis	A deductive approach that examines the pathways leading to a fault.	Best for complex problems requiring in-depth analytical approaches.

CAPA Strategy

Corrective and preventive actions (CAPA) are essential in addressing non-compliance effectively. A robust CAPA strategy includes:

Correction

• Identify specific instances of non-compliance and address them immediately.
• Ensure that all affected batches are appropriately handled (quarantine, testing, etc.).

Corrective Action

• Implement changes based on findings, such as revising supplier contracts or increasing audit frequency.
• Update training programs for personnel accounting for specific non-compliance issues identified.

Preventive Action

• Regularly review and revise quality agreements with suppliers to ensure compliance with WHO GMP.
• Establish a monitoring plan that includes scheduled audits and performance metrics.

Control Strategy & Monitoring

To ensure sustainable compliance, a strong control strategy and continuous monitoring are necessary. Key actions include:

Related Reads

• Ensuring Audit Readiness and Successful Regulatory Inspections in Pharma
• WHO Prequalification Compliance: A Complete Guide for Pharmaceutical Manufacturers

• Implement Statistical Process Control (SPC) to analyze and maintain quality levels.
• Establish trending systems for critical quality attributes to catch potential variations early.
• Employ alarms and alerts for critical deviations and ensure immediate responses are established.
• Utilize verification steps during batch processing to ensure compliance with the defined parameters.

Validation / Re-qualification / Change Control Impact

Supplier WHO GMP non-compliance often necessitates a review of your validation strategy and may trigger the need for re-qualification or change control:

• Evaluate if the non-compliance changes assumptions made during previous validations.
• Re-qualify processes or equipment impacted by the non-compliance to ensure continued effectiveness.
• Appropriate change control processes should be followed for any modifications to supplier agreements or sourcing strategies.

Inspection Readiness: What Evidence to Show

To be prepared for inspections, it is crucial to have comprehensive documentation to support your compliance actions. Key documents include:

• Records of all audits completed and findings that resulted in corrective actions.
• Documentation of CAPA activities, from initiation to completion.
• Batch records, logs, and deviations related to the non-compliant supplier.
• Ongoing monitoring reports that track metrics over time to assess compliance stability.

FAQs

What should I do if a supplier fails an internal audit?

Immediately initiate a CAPA process, including containment actions, while engaging with the supplier to address the identified issues.

How can I ensure that my CAPA strategy is effective?

Regularly review and update CAPA procedures, monitor outcomes, and adjust strategies based on both internal assessments and regulatory feedback.

What are the common consequences of WHO GMP non-compliance?

Consequences can include product recalls, increased regulatory scrutiny, financial penalties, and damage to the company’s reputation.

How often should supplier audits be conducted?

Frequency should depend on risk assessments, supplier performance history, and the criticality of the materials supplied.

What is the role of quality agreements with suppliers?

Quality agreements define the expectations for compliance with GMP standards and detail responsibilities in terms of quality management.

How does a lack of training contribute to non-compliance?

Personnel without adequate training may not adhere to GMP requirements, leading to errors in processing, quality control, and documentation.

What documentation is required for an inspection following a non-compliance incident?

Inspectors will look for complete audit trails, CAPA documentation, training records, and any relevant communications with suppliers regarding compliance.

What strategies can mitigate the risk of supplier non-compliance?

Developing strong relationships with suppliers, conducting regular audits, and having robust quality agreements can significantly reduce risks.